Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis

Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be presen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez Polo, Virginia, Pucci Molineris, Melisa Eliana, Cervera, Victorio, Gambaro, Sabrina Eliana, Yantorno, Silvina E., Descalzi, Valeria, Tiribelli, Claudio, Gondolesi, Gabriel Eduardo, Meier, Dominik
Formato: Articulo
Lenguaje:Inglés
Publicado: 2019
Materias:
Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
Acceso en línea:http://sedici.unlp.edu.ar/handle/10915/162649
Aporte de:
SEDICI (UNLP) de Universidad Nacional de La Plata
id I19-R120-10915-162649
record_format dspace
spelling I19-R120-10915-1626492024-02-15T13:35:20Z http://sedici.unlp.edu.ar/handle/10915/162649 Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis Gonzalez Polo, Virginia Pucci Molineris, Melisa Eliana Cervera, Victorio Gambaro, Sabrina Eliana Yantorno, Silvina E. Descalzi, Valeria Tiribelli, Claudio Gondolesi, Gabriel Eduardo Meier, Dominik 2019-03-01 2024-02-14T17:19:56Z en Ciencias Médicas Liver disease ILC2 Autoimmune hepatitis Steatohepatitis Viral hepatitis Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target. Consejo Nacional de Investigaciones Científicas y Técnicas Facultad de Ciencias Médicas Articulo Articulo http://creativecommons.org/licenses/by-nc-nd/4.0/ Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) application/pdf 366-372
institution Universidad Nacional de La Plata
institution_str I-19
repository_str R-120
collection SEDICI (UNLP)
language Inglés
topic Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
spellingShingle Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
Gonzalez Polo, Virginia
Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
topic_facet Ciencias Médicas
Liver disease
ILC2
Autoimmune hepatitis
Steatohepatitis
Viral hepatitis
description Introduction: The interleukin-33/interleukin-13 pathway is involved in the immunopathology of liver fibrosis and recently characterized group 2 innate lymphoid cells (ILC2) were identified as profibrotic immune cells in the liver of mouse models. Our aim was to elucidate whether ILC2 might be present in human liver tissue and whether ILC2 contribute to liver fibrosis. Materials and methods: To identify ILC2 in liver tissue and blood, we purified mononuclear immune cells from needle biopsies, cirrhotic explant specimen, and paired peripheral blood samples. Cell suspensions were incubated with specific markers for ILC2 and analyzed by flow cytometry. The CD69 marker was included to assess the activation level of ILC2. In addition, we determined the IL-33 plasma level. Results: Results were correlated with the METAVIR fibrotic score of patients enrolled in this study. We detected ILC2 in a higher percentage of CD45+ cells in liver tissue than in paired peripheral blood. The number of ILC2 was significantly increased in fibrotic tissue, but only slightly increased in paired peripheral blood. A higher percentage of CD69+ ILC2 was observed in fibrotic tissue, and this increase correlates positively with aggravation of liver fibrosis measured by fibrotic METAVIR score. A higher level of plasma IL-33 was only detected in samples obtained from cirrhotic patients. Conclusion: Our study indicates that ILC2 are present in the human liver and are activated in tissue contributing to the immunopathology of human liver fibrosis, independently of the etiology; which might be a potential new therapeutic target.
format Articulo
Articulo
author Gonzalez Polo, Virginia
Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
author_facet Gonzalez Polo, Virginia
Pucci Molineris, Melisa Eliana
Cervera, Victorio
Gambaro, Sabrina Eliana
Yantorno, Silvina E.
Descalzi, Valeria
Tiribelli, Claudio
Gondolesi, Gabriel Eduardo
Meier, Dominik
author_sort Gonzalez Polo, Virginia
title Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_short Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_full Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_fullStr Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_full_unstemmed Group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
title_sort group 2 innate lymphoid cells exhibit progressively higher levels of activation during worsening of liver fibrosis
publishDate 2019
url http://sedici.unlp.edu.ar/handle/10915/162649
work_keys_str_mv AT gonzalezpolovirginia group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT puccimolinerismelisaeliana group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT cerveravictorio group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT gambarosabrinaeliana group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT yantornosilvinae group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT descalzivaleria group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT tiribelliclaudio group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT gondolesigabrieleduardo group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
AT meierdominik group2innatelymphoidcellsexhibitprogressivelyhigherlevelsofactivationduringworseningofliverfibrosis
_version_ 1807222426741768192

Ejemplares similares